Bicycle Therapeutics Statistics
Share Statistics
Bicycle Therapeutics has 69.02M shares outstanding. The number of shares has increased by 82.19% in one year.
| Shares Outstanding | 69.02M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.11% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 65.57M |
| Failed to Deliver (FTD) Shares | 1.53K |
| FTD / Avg. Volume | 0.25% |
Short Selling Information
The latest short interest is 3.43M, so 4.98% of the outstanding shares have been sold short.
| Short Interest | 3.43M |
| Short % of Shares Out | 4.98% |
| Short % of Float | 5.24% |
| Short Ratio (days to cover) | 4.87 |
Valuation Ratios
The PE ratio is -3.56 and the forward PE ratio is -6.6.
| PE Ratio | -3.56 |
| Forward PE | -6.6 |
| PS Ratio | 23.85 |
| Forward PS | 20.7 |
| PB Ratio | 1.73 |
| P/FCF Ratio | -10.12 |
| PEG Ratio | n/a |
Enterprise Valuation
Bicycle Therapeutics has an Enterprise Value (EV) of 162.04M.
| EV / Earnings | -0.9 |
| EV / Sales | 6.01 |
| EV / EBITDA | -0.88 |
| EV / EBIT | -0.85 |
| EV / FCF | -2.55 |
Financial Position
The company has a current ratio of 8.08, with a Debt / Equity ratio of 0.12.
| Current Ratio | 8.08 |
| Quick Ratio | 8.08 |
| Debt / Equity | 0.12 |
| Total Debt / Capitalization | 10.81 |
| Cash Flow / Debt | -1.35 |
| Interest Coverage | -58.21 |
Financial Efficiency
Return on equity (ROE) is -0.49% and return on capital (ROIC) is -46.04%.
| Return on Equity (ROE) | -0.49% |
| Return on Assets (ROA) | -0.3% |
| Return on Capital (ROIC) | -46.04% |
| Revenue Per Employee | 94.99K |
| Profits Per Employee | -636.14K |
| Employee Count | 284 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 1.46M |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -18.39% in the last 52 weeks. The beta is 0.89, so Bicycle Therapeutics's price volatility has been higher than the market average.
| Beta | 0.89 |
| 52-Week Price Change | -18.39% |
| 50-Day Moving Average | 18.77 |
| 200-Day Moving Average | 22.06 |
| Relative Strength Index (RSI) | 41.67 |
| Average Volume (20 Days) | 601.25K |
Income Statement
In the last 12 months, Bicycle Therapeutics had revenue of 26.98M and earned -180.66M in profits. Earnings per share was -5.08.
| Revenue | 26.98M |
| Gross Profit | 20.51M |
| Operating Income | -189.95M |
| Net Income | -180.66M |
| EBITDA | -183.40M |
| EBIT | -189.95M |
| Earnings Per Share (EPS) | -5.08 |
Balance Sheet
The company has 526.42M in cash and 44.96M in debt, giving a net cash position of 481.47M.
| Cash & Cash Equivalents | 526.42M |
| Total Debt | 44.96M |
| Net Cash | 481.47M |
| Retained Earnings | -511.76M |
| Total Assets | 996.75M |
| Working Capital | 909.79M |
Cash Flow
In the last 12 months, operating cash flow was -60.63M and capital expenditures -2.93M, giving a free cash flow of -63.56M.
| Operating Cash Flow | -60.63M |
| Capital Expenditures | -2.93M |
| Free Cash Flow | -63.56M |
| FCF Per Share | -1.79 |
Margins
Gross margin is 76.03%, with operating and profit margins of -704.13% and -669.72%.
| Gross Margin | 76.03% |
| Operating Margin | -704.13% |
| Pretax Margin | -664.32% |
| Profit Margin | -669.72% |
| EBITDA Margin | -679.86% |
| EBIT Margin | -704.13% |
| FCF Margin | -235.61% |
Dividends & Yields
BCYC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -34.28% |
| FCF Yield | -6.21% |
Analyst Forecast
The average price target for BCYC is $32, which is 115.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $32 |
| Price Target Difference | 115.9% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Scores
| Altman Z-Score | 3.34 |
| Piotroski F-Score | 3 |